# Clinical Study of YS110 in Patients With Malignant Pleural Mesothelioma

> **NCT03177668** · PHASE1,PHASE2 · COMPLETED · sponsor: **Kissei Pharmaceutical Co., Ltd.** · enrollment: 40 (actual)

## Conditions studied

- Malignant Pleural Mesothelioma

## Interventions

- **DRUG:** YS110

## Key facts

- **NCT ID:** NCT03177668
- **Lead sponsor:** Kissei Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-08-08
- **Primary completion:** 2020-02-05
- **Final completion:** 2020-02-05
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2020-09-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03177668

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03177668, "Clinical Study of YS110 in Patients With Malignant Pleural Mesothelioma". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03177668. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*